Gilead/Galapagos alliance hit again as IPF drug is binnedGilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage Share XGilead/Galapagos alliance hit again as IPF drug is binnedhttps://pharmaphorum.com/news/gilead-galapagos-alliance-hit-again-as-ipf-drug-is-binned/
Prescient Healthcare Group to Partner with Bridgepoint Development CapitalThe partnership will further enhance the client value Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Blue Oak taps AI specialist Exscientia for CNS drug discoveryUS startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK Share XBlue Oak taps AI specialist Exscientia for CNS drug discoveryhttps://pharmaphorum.com/news/blue-oak-taps-ai-specialist-exscientia-for-cns-drug-discovery/
Moderna broadens R&D scope with Vertex, Chiesi alliancesAll eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle Share XModerna broadens R&D scope with Vertex, Chiesi allianceshttps://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/
Google pumps $100m into Amwell as telehealth firm eyes IPOIt’s all go in the US telehealth sector, with Alphabet’s Google investing $100 million in Amwell on the Share XGoogle pumps $100m into Amwell as telehealth firm eyes IPOhttps://pharmaphorum.com/news/google-pumps-100m-into-amwell-as-telehealth-firm-eyes-ipo/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
Sanofi sheds Regeneron stake, but insists collaboration is unaffectedSanofi and Regeneron’s once close relationship has been become a little more distant over the last couple of Share XSanofi sheds Regeneron stake, but insists collaboration is unaffectedhttps://pharmaphorum.com/news/sanofi-sheds-regeneron-stake-but-insists-collaboration-is-unaffected/
Roche hops on Bicycle’s drug discovery platform for cancerRoche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics – Share XRoche hops on Bicycle’s drug discovery platform for cancerhttps://pharmaphorum.com/news/roche-hops-on-bicycles-drug-discovery-platform-for-cancer/